Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
----------
AIM - WINNERS
----------
Kromek Group PLC, up 14% at 8.00 pence, 12-month range 3.00p-8.50p. The detection technology supplier is awarded a contract, worth up to USD2.9 million, from a "US federal entity" for the provision of nuclear security products. The contract, which is from an existing customer, covers the provision of the company's D5 RIID, D3M and D3S-ID wearable high-performance radiation detectors. Kromek has received a USD358,000 order under this contract for immediate delivery, with up to USD2.5 million to be awarded over the next 24 months.
----------
Cordel Group PLC, up 10% at 4.18p, 12-month range 3.10p-7.00p. Cordel's flagship platform uses artificial intelligence to supply transport corridor analytics. Cordel announces an agreement with a "major national railway" in the Asia Pacific region. The customer has agreed to proceed with a 12-week paid trial of Cordel's forward-facing video solution. Chief Executive John Davis says: "We are delighted to welcome a new major customer, with a 4,000 kilometre rail network which is being reinvigorated by unprecedented government investment, including a digital engineering programme, which utilises the best digital technology to improve network performance, safety and efficiency."
----------
AIM - LOSERS
----------
Destiny Pharma PLC, down 29% at 15.30p, 12-month range 13.20p-84.00p. The biotechnology company reports loss from operations of GBP6.7 million in 2023, narrowed from GBP7.8 million a year earlier. Pretax loss narrows to GBP6.4 million from GBP7.7 million. "During 2023 we intensified partnering activities for our lead asset, XF-73 nasal, and completed US market analysis that confirmed the significant market opportunity for this asset of up to $1 billion in the US alone. We also continued to progress the scale-up manufacture required for Phase 3 clinical studies and commercialisation. Our target remains progressing XF-73 nasal into Phase 3 clinical studies as quickly as possible," says Chief Financial Officer Shaun Claydon.
----------
By Sophie Rose, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
